Agilent Technologies (NYSE: A) moved nicely higher on Monday
behind a new portable measurement device.

Chart Courtesy of StockCharts.com
Gas chromatography isn't exactly dinner conversation, but
it is important in chemistry and more important in drug testing,
which is becoming a much more frequent development in the
work place these days.
Agilent seems to have a potential hit on its hand with its new portable gas chromatographer,
which according to a company press release is "the industry's first commercial
transportable GC/MS system that delivers laboratory-quality analysis." In other
words, if the new product delivers, it will make it easier for more people to
do more testing with less bulk and less expense.
And perhaps this is what's more important, you can take this thing anywhere.
The press release notes: "The 5975T LTM GC/MSD is particularly well-suited for
chemical warfare analysis, first responders, and military and homeland security
officials who need fast and highly accurate results in the field. Additional
out-of-laboratory applications include food safety testing and environmental
monitoring. "
You got it, it's got a military and a disater application, which means that anything
from water testing to perhaps even criminal and forensic investigations may become
easier to perform out in the field.
To the average person this may sound like inside basebal. But to investors, the
breakout on the stock suggests that big money folks seem to like the idea of
being able to take the lab on the road for quicker evaluation of samples and
faster, more informed decision making during tough situations.
Agilent's breakout is also part of a much larger picture that is emerging in
the stock market. And that is that lots of stocks outside the mainstream are
starting to make big moves.
Make money if any market rises or falls, with a copy of "Market Timing For Dummies."
“Futures And Options For Dummies,” Dr. Duarte’s
latest book is now available. The markets are responding to news
and geopolitical developments like never before. In this environment,
individual investors need to expand their investment horizons. "Futures And Options For Dummies " (John Wiley & Sons)
has an excellent section on oil futures as well as the currency markets,
while covering and expanding on the successful strategies in Doctor
Duarte's other books. Order your copy today.
Doctor Joe Duarte's Market I.Q., offers subscribers a unique blend of intelligence, market commentary and trading strategy. Duarte's daily articles, and news summaries offer recommendations and analysis for ETFs, and individual stocks in the technology, health and biotechnology, and energy sectors. Doctor Duarte is a writer, and an emerging futurist, with a diverse background, and a growing audience. His combined expertise in health care, energy, and the effects of politics and global intelligence on the financial markets offer a unique blend of insight and information to thousands of active investors and political and intelligence aficionados around the world on a daily basis.
He is the author of four books: "Futures And Options For Dummies," "Successful Energy Sector Investing," "Successful Biotech Investing" and co-author of "After-Hours Trading Made Easy."
In early 2001 Dr. Duarte in "Successful Energy Sector Investing," correctly predicted that Venezuela's political problems could lead to an energy crisis in the United States.
In 2003, also Dr. Duarte was among the first to widely publicize the long-term friendship between French President Jacques Chirac and Saddam Hussein.
He has also appeared as a weekly guest on Market Mavens Radio, has logged appearances on KNX radio in Los Angeles, Financial Sense.com radio, and Wall Street Radio.
One of CNBC's original Market Mavens, Dr. Duarte has been writing about the financial markets since 1990.
His articles and commentary have been featured on CBS Marketwatch, Barron's, Smart Money, Medical Economics, and in Technical Analysis of Stocks and Commodities magazines.
In 2003, Doctor Duarte received second place, in the professional section, of the Medical Economics Investment Challenge with a 12-month return of 42%.
Joe-Duarte.com is independently operated and solely funded by subscriber fees. This web site and the content provided is meant for educational purposes only and is not a solicitation to buy or sell any securities or investments. All sources of information are believed to be accurate, or as otherwise stated. Dr. Duarte and the publishers, partners, and staff of Joe-Duarte.com have no financial interest in any of the sources used. For independent investment advice consult your financial advisor. The analysis and conclusions reached on Joe-Duarte.com are the sole property of Dr. Joe Duarte.
|